Bundamedik Tbk Pt Stock Gross Profit
| BMHS Stock | 268.00 2.00 0.74% |
Bundamedik Tbk PT fundamentals help investors to digest information that contributes to Bundamedik Tbk's financial success or failures. It also enables traders to predict the movement of Bundamedik Stock. The fundamental analysis module provides a way to measure Bundamedik Tbk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bundamedik Tbk stock.
Bundamedik |
Bundamedik Tbk PT Company Gross Profit Analysis
Bundamedik Tbk's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Bundamedik Tbk Gross Profit | 799.78 B |
Most of Bundamedik Tbk's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bundamedik Tbk PT is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Bundamedik Tbk PT reported 799.78 B of gross profit. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Care Facilities industry. The gross profit for all Indonesia stocks is significantly lower than that of the firm.
Bundamedik Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bundamedik Tbk's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bundamedik Tbk could also be used in its relative valuation, which is a method of valuing Bundamedik Tbk by comparing valuation metrics of similar companies.Bundamedik Tbk is currently under evaluation in gross profit category among its peers.
Bundamedik Fundamentals
| Return On Equity | 0.0811 | |||
| Return On Asset | 0.0465 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 3.68 T | |||
| Shares Outstanding | 8.6 B | |||
| Shares Owned By Insiders | 78.80 % | |||
| Price To Book | 2.14 X | |||
| Price To Sales | 2.17 X | |||
| Revenue | 1.71 T | |||
| Gross Profit | 799.78 B | |||
| EBITDA | 291.45 B | |||
| Net Income | 215.3 B | |||
| Total Debt | 225.96 B | |||
| Book Value Per Share | 186.41 X | |||
| Cash Flow From Operations | 260.04 B | |||
| Earnings Per Share | 30.71 X | |||
| Target Price | 855.0 | |||
| Number Of Employees | 1.16 K | |||
| Market Capitalization | 3.61 T | |||
| Total Asset | 2.69 T | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 2.69 T | |||
| Last Dividend Paid | 2.56 |
About Bundamedik Tbk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bundamedik Tbk PT's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bundamedik Tbk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bundamedik Tbk PT based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Bundamedik Stock
Bundamedik Tbk financial ratios help investors to determine whether Bundamedik Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bundamedik with respect to the benefits of owning Bundamedik Tbk security.